|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: WHO
classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shibuya M: Pathology and molecular
genetics of meningioma: Recent advances. Neurol Med Chir (Tokyo).
55:14–27. 2015. View Article : Google Scholar
|
|
3
|
Jennifer M, Cope WP, Vartanian ED, Reiner
AS, Kellen R, Ogilvie SQ, Huse JT and Gutin PH: Survival in
patients treated for anaplastic meningioma. J Neurosurg. 123:23–30.
2015. View Article : Google Scholar
|
|
4
|
Cain SA, Smoll NR, Van Heerden J, Tsui A
and Drummond KJ: Atypical and malignant meningiomas: Considerations
for treatment and efficacy of radiotherapy. J Clin Neurosci.
22:1742–1748. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dittrich A, Gautrey H, Browell D and
Tyson-Capper A: The HER2 signaling network in breast cancer - Like
a spider in its web. J Mammary Gland Biol Neoplasia. 19:253–270.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tai W, Mahato R and Cheng K: The role of
HER2 in cancer therapy and targeted drug delivery. J Control
Release. 146:264–275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ménard S, Casalini P, Campiglio M, Pupa SM
and Tagliabue E: Role of HER2/neu in tumor progression and therapy.
Cell Mol Life Sci. 61:2965–2978. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vernimmen D, Gueders M, Pisvin S, Delvenne
P and Winkler R: Different mechanisms are implicated in ERBB2 gene
over-expression in breast and in other cancers. Br J Cancer.
89:899–906. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mahzouni P and Movahedipour M: An
immunohistochemical study of HER2 expression in meningioma and its
correlation with tumor grade. Pathol Res Pract. 208:221–224. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schwechheimer K, Läufle RM, Schmahl W,
Knödlseder M, Fischer H and Höfler H: Expression of neu/c-erbB-2 in
human brain tumors. Hum Pathol. 25:772–780. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schlegel J, Ullrich B, Stumm G, Gass P,
Harwerth IM, Hynes NE and Kiessling M: Expression of the
c-erbB-2-encoded oncoprotein and progesterone receptor in human
meningiomas. Acta Neuropathol. 86:473–479. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chozick BS, Benzil DL, Stopa EG, Pezzullo
JC, Knuckey NW, Epstein MH, Finkelstein SD and Finch PW:
Immunohistochemical evaluation of erbB-2 and p53 protein expression
in benign and atypical human meningiomas. J Neurooncol. 27:117–126.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang W, Tu Y, Wang S, Xu S, Xu L, Xiong Y,
Mei J and Wang C: Role of HER-2 activity in the regulation of
malignant meningioma cell proliferation and motility. Mol Med Rep.
12:3575–3582. 2015.PubMed/NCBI
|
|
14
|
De Luca A, Maiello MR, D'Alessio A,
Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT
signalling pathways: role in cancer pathogenesis and implications
for therapeutic approaches. Expert Opin Ther Targets. 16(Suppl 2):
S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Richman SD, Southward K, Chambers P, Cross
D, Barrett J, Hemmings G, Taylor M, Wood H, Hutchins G, Foster JM,
et al: HER2 overexpression and amplification as a potential
therapeutic target in colorectal cancer: Analysis of 3256 patients
enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.
J Pathol. 238:562–570. 2016. View Article : Google Scholar :
|
|
16
|
Ren W, Liu Y, Wan S, Fei C, Wang W, Chen
Y, Zhang Z, Wang T, Wang J, Zhou L, et al: BMP9 inhibits
proliferation and metastasis of HER2-positive SK-BR-3 breast cancer
cells through ERK1/2 and PI3K/AKT pathways. PloS One. 9:e968162014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang CL, Mei JH, Wang SS, Xu S, Xu LL and
Xiong YF: Expression of HER2/neu in meningiomas: An
immunohistochemistry and fluorescence in situ hybridization study.
Zhonghua Bing Li Xue Za Zhi. 39:156–160. 2010.In Chinese.
PubMed/NCBI
|
|
18
|
Yang L, Li Y and Zhang Y: Identification
of prolidase as a high affinity ligand of the ErbB2 receptor and
its regulation of ErbB2 signaling and cell growth. Cell Death Dis.
5:e12112014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Elster N, Collins DM, Toomey S, Crown J,
Eustace AJ and Hennessy BT: HER2-family signalling mechanisms,
clinical implications and targeting in breast cancer. Breast Cancer
Res Treat. 149:5–15. 2015. View Article : Google Scholar
|
|
20
|
Sun Y, Liu WZ, Liu T, Feng X, Yang N and
Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation,
differentiation, migration, senescence and apoptosis. J Recept
Signal Transduct Res. 35:600–604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pearson G, Robinson F, Beers Gibson T, Xu
BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein
(MAP) kinase pathways: Regulation and physiological functions.
Endocr Rev. 22:153–183. 2001.PubMed/NCBI
|
|
22
|
Rubinfeld H and Seger R: The ERK cascade:
A prototype of MAPK signaling. Mol Biotechnol. 31:151–174. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lochhead PA, Gilley R and Cook SJ: ERK5
and its role in tumour development. Biochem Soc Trans. 40:251–256.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu B, Ren D, Su D, Lin H, Xian Z, Wan X,
Zhang J, Fu X, Jiang L, Diao D, et al: Expression of the
phosphorylated MEK5 protein is associated with TNM staging of
colorectal cancer. BMC Cancer. 12:1272012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang X and Tournier C: Regulation of
cellular functions by the ERK5 signalling pathway. Cell Signal.
18:753–760. 2006. View Article : Google Scholar
|
|
26
|
Cellurale C, Girnius N, Jiang F,
Cavanagh-Kyros J, Lu S, Garlick DS, Mercurio AM and Davis RJ: Role
of JNK in mammary gland development and breast cancer. Cancer Res.
72:472–481. 2012. View Article : Google Scholar :
|
|
27
|
Li W, Wen C, Bai H, Wang X, Zhang X, Huang
L, Yang X, Iwamoto A and Liu H: JNK signaling pathway is involved
in piperlongumine-mediated apoptosis in human colorectal cancer
HCT116 cells. Oncol Lett. 10:709–715. 2015.PubMed/NCBI
|
